ArticleCell death & disease2021
The intrinsic role and mechanism of tumor expressed-CD38 on lung adenocarcinoma progression.
Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Emerging chemical strategies for CD38 inhibition: restoring NADBioorganic & medicinal chemistry · 2026Review
- CD38 overexpression drives glioblastoma progression via L1CAM/ICAM1/JAK-STAT-Driven tumor microenvironment rewiring.Translational oncology · 2026Article
- Development of a computed tomography radiomics and CD38 integrated model: predicting immunotherapy response and investigating biological implications in non-small cell lung cancer.Journal of thoracic disease · 2026Article
- Article
- Expression of CD38Scientific reports · 2026Article
- Wise as a Serpent and Gentle as a Dove: Pharmacological Targeting of NRF2/KEAP1 Pathway from Treasure Trove of Mother Nature.Drug design, development and therapy · 2026Review
- Regulating the regulators via targeting CD38 in the tumor microenvironment.Frontiers in immunology · 2026Review
- CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer.Translational oncology · 2025Article
- Macrophage Transcriptomic Alterations Driven by Alphavirus-Based Cancer Immunotherapy Vectors.Journal of immunology research · 2025Article
- Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis.Frontiers in immunology · 2025Review
- Development of New CD38 Targeted Peptides for Cancer Imaging.Molecular imaging and biology · 2024Article
- Comprehensive proteomic profiling of lung adenocarcinoma: development and validation of an innovative prognostic model.Translational cancer research · 2024Article
- Article
- Role of CD38 in anti-tumor immunity of small cell lung cancer.Frontiers in immunology · 2024Article
- Evolving roles of CD38 metabolism in solid tumour microenvironment.British journal of cancer · 2023Review
- Review
- Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment.Cancer cell international · 2022Review
- Simultaneous multiple myeloma and non-small cell lung carcinoma: A case report and review of the literature.Oncology letters · 2022Article
- Article
- Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy.Journal for immunotherapy of cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
It has been recently reported that CD38 expressed on tumor cells of multiple murine and human origins could be upregulated in response to PD-L1 antibody therapy, which led to dysfunction of tumor-infiltrating CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.